Evidence map›Paper›PMID 36077111›Full record

ArticleInternational journal of molecular sciences2022

Primary TSC2

Clara Bernardelli, Eloisa Chiaramonte, Silvia Ancona, Silvia M Sirchia, Amilcare Cerri, Elena Lesma

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Editorial: Special Issue, "Molecular Advances in Skin Diseases".International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Clara BernardelliLaboratory of Pharmacology, Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy.ORCID 0000-0002-3813-9038
Eloisa ChiaramonteLaboratory of Pharmacology, Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy.
Silvia AnconaLaboratory of Pharmacology, Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy.ORCID 0000-0003-1999-129X
Silvia M SirchiaMedical Genetics, Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy.ORCID 0000-0002-6106-3721
Amilcare CerriDermatology Unit, Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy.
Elena LesmaLaboratory of Pharmacology, Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy.ORCID 0000-0002-9096-713X
University of Milan · IT

Funding

AiLAM Onlus RV_LIB16_MST Associazione Sclerosi Tuberosa LIB_VT17
6 · The paper itself

Abstract

Cutaneous lesions are one of the hallmarks of tuberous sclerosis complex (TSC), a genetic disease in which mTOR is hyperactivated due to the lack of hamartin or tuberin. To date, novel pharmacological treatments for TSC cutaneous lesions that are benign but still have an impact on a patient's life are needed, because neither surgery nor rapamycin administration prevents their recurrence. Here, we demonstrated that primary TSC2

Indexed as

Tuberous SclerosisAnimalsMiceMice, NudeTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins5-azacytidinecellular migrationfollicular neogenesismTORprimary cellstuberous sclerosis complex

Identifiers

PMID36077111
PMCPMC9456283
OpenAlexW4293539935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.